Anika Therapeutics, Inc. provided revenue guidance for the year 2022. The company expects its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021. Revenue ranges by product family are: Joint Preservation and Restoration up mid-single to low-double digit percent.

OA Pain Management up low-single digit percent Non-Orthopedic revenue down approximately 20% due largely to legacy product rationalization.